<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060310152055+01'00'</creation_date><modification_date>D:20060322110453+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-273_h_a_dec_1.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 28-ii-2006 c(2006) 693 
 not for publication</p></section><section><header>commission decision of 28-ii-2006 
 amending the marketing authorisation for &quot;lysodren - mitotane&quot;, a medicinal 
 product for human use, granted by decision c(2004)1765 
 (text with eea relevance)</header><p>(only the french text is authentic)</p></section><section><header>en  
   en</header></section><section><header>commission decision of 28-ii-2006 
 amending the marketing authorisation for &quot;lysodren - mitotane&quot;, a medicinal 
 product for human use, granted by decision c(2004)1765 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorisation and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 2, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 3, and in particular the third subparagraph of article 4(5) thereof, 
 having regard to the notifications submitted by laboratoire hra pharma under article 
 4(1) of regulation (ec) no 1085/2003, 
 whereas: 
 (1)</p><p>the european medicines agency acknowledged, between 1 august 2005 and 1 
 february 2006, the validity of the notification(s) for minor variations of type ia, 
 informing the marketing authorisation holder accordingly, and has prepared a list 
 of the notification(s). the variation(s) took effect from the date of the 
 communication from the european medicines agency concerning the validation.</p><p>
 1 oj l 214, 24.8.1993, p. 1. regulation as last amended by regulation (ec) no 1647/2003 (oj l 245, 29.9.2003, p. 19). 
 2 oj l 136, 30.4.2004, p. 1 3 oj l 159, 27.6.2003, p. 24.</p></section><section><header>en  
   en</header><p>(2) the marketing authorisation should be updated, and decision c(2004)1765 of 28 
 april 2004 amended accordingly. 
 (3)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c (2004)1765 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)1765 is amended as follows: 1) the following list of notifications for minor variations is added to the updated 
 marketing authorisation. 
 application number 
 scope (eu numbers affected) 
 emea/h/c/521/ia/0002 
 1 (ia) (eu/1/04/273/001) 
 emea/h/c/521/ia/0003 
 6.a (ia) (eu/1/04/273/001) 
 2) annex iii is replaced by the text set out in the annex iii to this decision. 
 article 2 this decision is addressed to laboratoire hra pharma, 19 rue frédérick lemaître 75020 paris, france. 
 done at brussels, 28-ii-2006 
 for the commission günter verheugen 
 vice-president of the commission</p></section></body></xml>